D3 Pharma and Encap Drug Delivery Continue Partnership
News Jun 19, 2012
D3 Pharma Limited has announced its continuing partnership with Encap Drug Delivery to expedite the commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D3 product, Plenachol™, for the treatment of vitamin D deficiency and insufficiency.
Plenachol™ is a patented liquid-filled capsule formulation of vitamin D3 which was developed in conjunction with Encap and is available at three dose-strengths: 20,000, 40,000 and 100,000 international units.
Plenachol™ has a unique formulation base which is free from animal derived excipients and peanut constituents.
The utility of Encap’s world-class capsule liquid-filling technology secures Plenachol™ as a first and best-in-class high-dose oral vitamin D 3 product.
Plenachol™ will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery.
For more information regarding Plenachol™ Specials supply please contact: Dr Janice McLachlan (JMcLachlan@encapdrugdelivery.com).
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019